Citigroup
IMVT icon

Citigroup’s Immunovant IMVT Stock Holding History

Citigroup’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,200
Closed -$1.01M – 5770
2025
Q1 		$1.01M Hold
59,200
– – ﹤0.01% 3255
2024
Q4 		$1.47M Buy
59,200
+29,700
+101% +$842K ﹤0.01% 3061
2024
Q3 		$841K Buy
+29,500
New +$870K ﹤0.01% 3393
2023
Q2 		– Sell
-38,900
Closed -$603K – 5637
2023
Q1 		$603K Buy
+38,900
New +$675K ﹤0.01% 2981

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Citigroup's IMVT Position: Q1 2026 in Review

Citigroup increased its Immunovant (IMVT) stake by 11% in Q1 2026, buying an estimated $63.8K and bringing the position to 25,350 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #3406.

Citigroup first reported a position in IMVT in Q1 2020 and has held it in 25 quarters since. The position peaked at $8.07M in Q1 2024. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Citigroup held 25,350 shares of Immunovant worth $630K as of Q1 2026.
  • Citigroup bought 2,465 Immunovant shares in Q1 2026, an estimated $63.8K.
  • Immunovant made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3406 holding.
  • Citigroup first reported a position in Immunovant in Q1 2020 and has held it in 25 quarters since.
  • Citigroup's Immunovant position peaked at $8.07M in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.